Core Viewpoint - The company Shijiazhuang Pharmaceutical Group (02005) is experiencing a significant decline in stock price, dropping over 7% following the announcement of a projected profit decrease for the fiscal year 2025, which is expected to fall by 45%-60% compared to the previous year's profit of 1.061 billion HKD [1] Group 1: Financial Performance - The company anticipates a profit decline for the fiscal year 2025, projecting earnings to decrease by 45%-60% from the previous year's 1.061 billion HKD [1] - The expected decline is attributed to a lack of large-scale epidemics in 2025, which will lead to decreased sales of pharmaceuticals due to reduced market demand [1] Group 2: Market Conditions - The first quarter of 2024 saw a surge in demand for intravenous infusions and other pharmaceuticals due to a domestic flu outbreak, but this demand is not expected to continue into 2025 [1] - The expansion of various forms of bulk purchasing, including national and local drug procurement, is expected to exert continuous price pressure on the company [1] - Increased competition within the domestic and international pharmaceutical industry is contributing to the ongoing pricing challenges faced by the company [1] Group 3: Product-Specific Issues - The revenue from the product Ambroxol Hydrochloride Injection is expected to decline as it will no longer be sold through national drug procurement channels [1]
港股异动 | 石四药集团(02005)跌超7% 预计2025年度溢利同比下降约45%至60%